Directorate Change

11 May 2006 07:00

Embargoed: 0700hrs, 11 May 2006 AKERS BIOSCIENCES, INC. ("Akers" or the "Company") Appointment of a Director Akers Biosciences, Inc., the United States based developer, manufacturer, andsupplier of rapid, point of care screening and testing products, is pleased toannounce the appointment of Thomas A. Nicolette as Non-Executive Director,effective immediately. Akers believes that Mr. Nicolette's background in sales,manufacturing and experience as Chief Executive Officer of several companiespublicly listed in the U.S. will be of great benefit to the Company.Mr. Nicolette replaces Geoffrey Vero on the Company's Board of Directors, whoseterm as Non-Executive Director expires in 90 days, ensuring an orderlytransition. The Company wishes to thank Mr. Vero for his service to the Board,and his capable leadership of the Audit Committee.The directorships held by Mr. Nicolette, aged 55, over the five years precedingthe date of appointment are as follows:Current directorshipsSenTech EAS CorporationDirector - Corporate Secretary and TreasurerDesigns, manufacturers, installs and services Electronic Security Systems forretail, commercial and industrial firms. Based in Pompano Beach, FloridaIDENTIF GmbHDirector - International Business DevelopmentHas developed patented new methods of authentication based on molecular andoptical markings used for anti-counterfeiting. Based in Erlangen, Germany.Global Securities Technologies, Inc. Chairman of the BoardBased in San Juan, Puerto Rico.Former directorships held during last five yearsEXAQT SA DE CVChairman of the BoardDesigns, manufacturers, installs and services Electronic Security Systems forretail, commercial and industrial firms. Based in Mexico City, Mexico.TRI-MEX Group LimitedExecutive DirectorHas developed monitoring and response solutions to protect high value and/orhazardous cargo in transit on land and sea. Based in London with operations inOslo, Norway.CROSSOFF, Inc.DirectorServed as president of DNAT and a Director of CrossOff, Inc. (TSE:OFF) based inLos Angeles, California.DNA TECHNOLOGIES, INC.Chairman and PresidentChief Executive Officer, DirectorOwns patented technology which has harnessed the power of genetic code,providing a solution to the problems of counterfeiting, forgery and productdiversion. Sold to CrossOff, Inc. in October 2001. Based in Halifax, NovaScotia, Canada.The Company has granted Mr. Nicolette an option to subscribe for 110,000 CommonShares. The exercise price of such options will be $1.32 per Common Share. Theoptions shall vest as follows: 47,000 options will vest six months after thedate of appointment and the balance of options will vest in 18 equal monthlyinstallments of 3,500 options per completed month of service as a Non-ExecutiveDirector commencing six months after the date of appointment.There is no further information required to be disclosed pursuant to the AIMRules.For further information please contact:Dr. Ray Akers Chief Executive Officer, Akers 020 7917 9476 Biosciences, Inc. Paul Freedman 001 856 848 8698 Chief Financial Officer, Akers Biosciences, Inc. Bill Roberts CTC, Inc. 001 937 434 2700 Ben Simons Hansard Communications 020 7245 1100 ENDAKERS BIOSCIENCES INC